What is the dose of propranolol (beta blocker) for hyperthyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Propranolol for hyperthyroidism is typically dosed at 10-40 mg taken orally three to four times daily, with a total daily dose ranging from 30-160 mg. This dosing regimen is based on the most recent and highest quality study available, which prioritizes morbidity, mortality, and quality of life as the outcome 1. Treatment usually begins at a lower dose (such as 10-20 mg three times daily) and is gradually increased as needed based on symptom control. For thyroid storm, higher doses of 60-80 mg every 4 hours may be required initially. Propranolol works by blocking beta-adrenergic receptors, which helps control the sympathetic symptoms of hyperthyroidism such as tachycardia, tremor, anxiety, and heat intolerance. It does not affect the underlying thyroid hormone levels but provides symptomatic relief while definitive treatment (antithyroid medications, radioactive iodine, or surgery) takes effect. Some key points to consider when using propranolol for hyperthyroidism include:

  • Monitoring for potential side effects including bradycardia, hypotension, bronchospasm, and fatigue
  • Using propranolol cautiously in patients with asthma, COPD, heart failure, or diabetes
  • Avoiding abrupt cessation of propranolol as this may precipitate a withdrawal reaction
  • Considering alternative dosing regimens, such as 1 to 3.4 mg/kg per day, as reported in other studies 1 It is essential to note that the provided evidence does not directly address the use of propranolol for hyperthyroidism, but rather its use in other contexts, such as infantile hemangioma 1 and cardiovascular disease 1. However, based on the available information and general medical knowledge, the recommended dosing regimen for propranolol in hyperthyroidism is as stated above.

From the Research

Dose of Propranolol for Hyperthyroidism

  • The dose of propranolol required to achieve clinical compensation in hyperthyroid patients can range from 240 to 400 mg/day 2.
  • In some cases, doses of up to 480 mg/day may be necessary, although this may not produce clinical compensation in all patients 2.
  • A study found that propranolol at a dose of 160 mg daily can produce a beneficial clinical response in hyperthyroidism, similar to other beta-blockers such as atenolol, metoprolol, and nadolol 3.
  • The plasma level of propranolol has been found to be significantly correlated with the decrease in serum T3 and the increase in serum rT3, suggesting that individualized dosage may be necessary 4.

Factors Affecting Propranolol Dosage

  • The pharmacokinetics of propranolol can be affected by hyperthyroidism, with reduced bioavailability and increased clearance in the hyperthyroid state 5.
  • The dose of propranolol may need to be adjusted based on the patient's clinical response and serum hormone levels 4.
  • Other beta-blockers, such as sotalol, may have advantages over propranolol in the treatment of thyrotoxicosis due to their longer half-life and unaltered elimination in hyperthyroidism 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Propranolol and hyperthyroidism: sequential changes in serum iodothyronine (T4, T3, rT3) concentrations during therapy until clinical remission.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 1983

Research

Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.

European journal of clinical pharmacology, 1980

Research

Pharmacokinetics of propranolol and sotalol in hyperthyroidism.

European journal of clinical pharmacology, 1982

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.